Search clinical trials for: Pathological complete response

Total 25777 results

Merck Sharp & Dohme LLC

Recruiting

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without MK- 2870 in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

Non Small Cell Lung Cancer

United States, Israel, Taiwan
Wuhan Union Hospital, China

Not yet recruiting

Deep Learning Model Predicts Pathological Complete Response of Lung Cancer Following Neoadjuvant Immunochemotherapy

Non-small Cell Lung Cancer | Pathological Complete Response | Neoadjuvant Chemoimmunotherapy | Deep Learning Model
Fondazione Policlinico Universitario Agostino Gemelli...

Recruiting

Transcriptional and Epimetabolic Profile of Breast Carcinoma With Luminal or HER2+ or Locally Advanced Triple-negative Histotype in Patients With/Without Previous Clinical History of Metabolic Syndrome (PROMETA)

Breast Cancer | Metabolic Syndrome

Italy
Jiangxi Provincial Cancer Hospital

Recruiting

The Prognostic Value of the Degree of Pathological Response of Induction Chemotherapy for NPC

Nasopharyngeal Carcinoma | Tumor Microenvironment | Pathologic Complete Response

China
University Medical Center Groningen
Centre Hospitalier Universitaire de Nice; LungenClinic Grosshansdorf

Recruiting

Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Stage III NSCLC (MRD-LUNG)

Lung Cancer Stage III

France, Germany, Netherlands
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Omission of ALND in Breast Cancer Patients With Axillary pCR

Breast Cancer | Pathological Complete Response | Axillary Lymph Node Dissection | Neoadjuvant Systemic Therapy | Axillary Lymph

China
Shanghai Pulmonary Hospital, Shanghai, China
Zunyi Medical College; Ningbo HwaMei Hospital, Zhejiang, China; The First Affiliated...

Recruiting

Deep Learning Signature for Predicting Complete Pathological Response to Neoadjuvant Chemoimmunotherapy in Non-small Cell Lung Cancer

Non-small Cell Lung Cancer | Neoadjuvant Chemoimmunotherapy | Complete Pathological Response

China
Fifth Affiliated Hospital, Sun Yat-Sen University

Recruiting

The Efficacy and Safety of De-escalated Postoperative Radiotherapy in Locally Advanced HNSCC With pCR/MPR

Head and Neck Squamous Cell Carcinoma

China
Centre Leon Berard

Recruiting

Multiparametric Quantitative MRI and Response to Neoadjuvant Radiotherapy for Soft-tissue Sarcoma (SarQuantIRM)

Soft Tissue Sarcoma | Resectable Soft Tissue Sarcoma | Adult Soft Tissue Sarcoma

France
AstraZeneca
SWOG Clinical Trials Partnerships; Daiichi Sankyo

Recruiting

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

Breast Cancer

United States, China, Denmark, United Kingdom, Korea, Republic of, Canada, Germany, Italy, Belgium, Spain, Japan, France, Taiwan, Greece, Brazil, Sweden, Puerto Rico
University of Florida
National Institute of General Medical Sciences (NIGMS)

Recruiting

Pathological Myeloid Activation After Sepsis and Trauma

Sepsis | Trauma Injury | Immunosuppression | Chronic Critical Illness

United States
Guangdong Provincial People's Hospital

Recruiting

Patient-reported Outcomes in Preoperative Immunochemotherapy/Radiotherapy-treated Esophageal Cancer Patients (PICCRT)

Esophageal Squamous Cell Carcinoma | Immunotherapy | Patient-reported Outcomes

China
Seoul National University Hospital
Ministry of Health & Welfare, Korea

Recruiting

Omission of Breast Surgery for Breast Cancer Patients With pCR on MRI and Vacuum-assisted Biopsy After NST (OPTIMIST) (OPTIMIST)

Breast Cancer Invasive

Korea, Republic of
Zhenzhen Liu

Recruiting

Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer

Breast Cancer | Triple Negative Breast Cancer | Camrelizumab

China
YULISU
Ono Pharmaceutical Co. Ltd

Recruiting

Neoadjuvant Nivolumab for Upper Tract Urothelial Carcinoma

Upper Urinary Tract Urothelial Carcinoma

Taiwan
Ottawa Hospital Research Institute

Recruiting

Evaluating 6-months of HER2-targeted Therapy in Patients With HER2 Positive Early-stage Breast Cancer That Achieve a Pathological Complete Response to Neoadjuvant Systemic Therapy

Breast Cancer

Canada
Guangdong Provincial People's Hospital

Recruiting

MRI-based Approaches for Multi-parametric Model to Early Predict Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer (NeoMDSS)

Breast Cancer

China
Peking University First Hospital

Recruiting

Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapy

Neoadjuvant Therapy | Cisplatin | Immunotherapy | HER2-negative Breast Cancer | Pathological Complete Response | Vinorelbine

China
Zhejiang Cancer Hospital

Not yet recruiting

Neoadjuvant Short-course Radiotherapy Followed by the Combination of Immunotherapy and Chemotherapy in Locally Advanced Rectal Cancer

Locally Advanced Rectal Cancer

China
N.N. Petrov National Medical Research Center of...

Recruiting

Refusal of Breast Surgery in Patients With Breast Cancer With a Clinical Complete Response (cCR) After Neoadjuvant Systemic Therapy and a Confirmed Pathological Complete Response (pCR) Using Vacuum-assisted Biopsy (VAB) and Sentinel Lymph Node Biopsy (SLNB) (VAB)

Refusal of Breast Surgery in Patients With Breast Cancer With a cCR After NST and a Confirmed Pathological Complete Response (pCR) Using VAB and SLNB

Russian Federation
Centre Georges Francois Leclerc

Recruiting

Evaluation of the Accuracy of Percutaneous Biopsy by Vacuum-assisted Biopsy (VAB) to Assess Pathological Complete Response in Patients With Clinical and Radiological Complete Response After Neoadjuvant Chemotherapy (NeoVAB) (NeoVAB)

Vacuum-assisted Biopsy

France
Yanhong Deng

Recruiting

Local Excision Versus Total Mesorectal Excision In Pathological Complete Response (ypT0-1cN0) Mid- Or Low-Rectal Cancer After Neoadjuvant Therapy

Rectal Cancer | Surgery

China
Peking University People's Hospital
Xijing Hospital; Beijing Friendship Hospital; Peking Union Medical College Hospital and other collaborators

Recruiting

Effect of Concurrent Capecitabine-based Long-term Radiotherapy Followed by XELOX Plus TME in Patients With High Risk Rectal Cancer: a Multi-centers, Randomized Controlled, Open-Label Trial (EXPLORE)

Rectal Cancer | Pathological Complete Response | Disease Free Survival

China
The First Hospital of Jilin University
First Affiliated Hospital Xi'an Jiaotong University; Qingdao University; First... and other collaborators

Recruiting

Sequential Neo-adjuvant Chemotherapy Followed by Capecitabine Vs. Conventional Adjuvant Chemotherapy in Breast Cancer (NACVCAC)

Breast Neoplasm Female

China
Lund University
South Sweden Breast Cancer Group; Mrs. Berta Kamprad Foundation; U-CAN

Recruiting

Sweden Cancerome Analysis Network - Breast : Genomic Profiling of Breast Cancer (SCAN-B)

Breast Neoplasms

Sweden
Sun Yat-sen University
Zhejiang Cancer Hospital; First People's Hospital of Hangzhou; The First Affiliated... and other collaborators

Recruiting

Neoadjuvant Chemoradiotherapy vs. Chemotherapy With Radical Gastrectomy and Adjuvant Chemotherapy for Advanced Gastric Cancer (Neo-CRAG)

Gastric Cancer

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy

Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast Cancer AJCC v8 | Prognostic Stage IIIC Breast Cancer AJCC v8 | Breast Inflammatory Carcinoma

United States
Zhejiang Cancer Hospital

Completed

PTC Guiding Neoadjuvant Treatment in Breast Cancer

Pathological Conditions, Signs and Symptoms

China
Leiden University Medical Center
The Netherlands Cancer Institute; Borstkanker Onderzoek Groep; Comprehensive... and other collaborators

Suspended

Fasting Mimicking Diet Program to ImpRovE ChemoTherapy in Hormone Receptor Postive (HR+), HER2- Breast Cancer (DIRECT-2)

HER2-negative Breast Cancer | Hormone Receptor-positive Breast Cancer | Neoadjuvant Chemotherapy | Fasting Mimicking Diet | Pathological Complete Response | Objective Response Rate

Netherlands
Assistance Publique - Hôpitaux de Paris

Completed

Influence of Lengthening the Interval Between Radiochemotherapy and Surgery on Complete Pathological Response in Rectal Cancer (GRECCAR6)

Rectal Cancer

France
Mahidol University
Ramathibodi Hospital

Completed

A Cohort of Predictive Factor of Pathologic Complete Response After Preoperative Neoadjuvant in Rectum Cancer

Rectum Cancer

Thailand
Erasmus Medical Center
Maastricht University Medical Center; UMC Utrecht; Amphia Hospital

Completed

RISAS Procedure in Node Positive Breast Cancer Following NAC (RISAS)

Breast Neoplasm | Neoadjuvant Therapy | Pathological Complete Response | Axillary Lymph Nodes

Netherlands
Fondazione Policlinico Universitario Agostino Gemelli...
Viewray Inc.

Unknown

THeragnostic Utilities for Neoplastic DisEases of the Rectum by MRI Guided Radiotherapy (THUNDER2)

Locally Advanced Rectal Cancer | Pathological Complete Response | Neoadjuvant Chemoradiotherapy

Italy
IRCCS San Raffaele
Politecnico di Milano

Unknown

Monitoring Response to NAC and Prediction of pCR in Breast Cancer Patients Using Optical Imaging

Chemotherapy Effect | Breast Cancer Female

Italy
Hospital General Universitario Gregorio Marañon

Terminated

CPR Prediction After Neoadjuvant Using Excisional Biopsy By Radiofrequency In Breast Cancer From II-III UICC Stages.

Triple Negative, HER2+, Luminal B Breast Tumors (Stages II-III)in Female Patients

Spain
Heidelberg University
German Research Foundation

Completed

Diagnosis of Pathological Complete Response by Vacuum-assisted Biopsy After Neoadjuvant Chemotherapy in Breast Cancer (RESPONDER)

Breast Neoplasms

Germany
RenJi Hospital

Unknown

Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy

Inflammatory Breast Cancer | Invasive Ductal Breast Cancer | Tubular Breast Cancer | Mucinous Breast Cancer

China
Leiden University Medical Center
Amgen; Borstkanker Onderzoek Groep; Pink Ribbon Inc.

Completed

DIetary REstriction as an Adjunct to Neoadjuvant ChemoTherapy for HER2 Negative Breast Cancer (DIRECT)

Breast Cancer | Neoadjuvant Chemotherapy | Fasting Mimicking Diet | Pathological Complete Response

Netherlands
Heidelberg University

Completed

Diagnosis of Pathological Complete Response by Minimal Invasive Biopsy After Neoadjuvant Chemotherapy in Breast Cancer

Breast Neoplasms

Germany
UMC Utrecht
Maastro Clinic, The Netherlands

Unknown

RECTAL BOOST Study (RECTAL BOOST)

Rectal Cancer

Netherlands
Universitaire Ziekenhuizen KU Leuven

Completed

Neoadjuvant Bevacizumab, Capecitabine and Radiation Therapy With or Without Oxaliplatin Locally Advanced Rectal Cancer (AXEBEAM)

Locally Advanced Rectal Cancer

Belgium
Maria Sklodowska-Curie National Research Institute...

Unknown

Organ Preservation in Elderly Patients With Rectal Cancer

Rectal Cancer

Poland
Sun Ying-Shi

Completed

Predicting Pathological Complete Response of Rectal Cancer With Magnetic Resonance(MR) Radiomics

Locally Advanced Rectal Cancer

China
Novartis Pharmaceuticals

Completed

Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women

Breast Cancer

Canada, Italy, Czechia, United States, Belgium, Austria, Germany, Spain, Japan, Lebanon, Australia, Bulgaria, Israel, Netherlands, Colombia, Hong Kong, Brazil
Moroccan Society of Surgery

Completed

Predictive Factors of Disease-free Survival After Complete Pathological Response to Neoadjuvant Radiotherapy in Rectal Adenocarcinoma

Rectal Neoplasms

Morocco, Algeria
Instituto Nacional de Cancer, Brazil

Completed

Triple-negative Breast Cancer: a New Perspective on Biomarkers (TNBCbrazil)

Triple Negative Breast Cancer | Triple Negative Breast Neoplasms

Brazil
Zhiyong Yu

Unknown

Pathological Complete Response Rate in Locally Advanced Breast Cancer With FEC, EC-T, or TC as Neoadjuvant Chemotherapy

Breast Cancer | Neoadjuvant Chemotherapy | Pathological Complete Response
University of Toronto
University Health Network, Toronto

Terminated

Study of Tumor RNA Disruption Assay™ (RDA) (RnaDx)

Breast Neoplasms

Canada
Assistance Publique - Hôpitaux de Paris

Unknown

Assessment of Breast Cancer Response to Neoadjuvant Anthracycline-based Chemotherapy by FDG-PET and Molecular Markers

Breast Cancer | Breast Neoplasms

France
Centre Jean Perrin

Withdrawn

Contribution of MRI in the Evaluation of Apparent Diffusion Coefficient and Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer (ADC)

Assess the Variation of Apparent Diffusion Coefficient

Search clinical trials for: Pathological complete response

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Taiwan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations